Acorda Therapeutics says FDA agrees on MS drug trial design

(Reuters) - The FDA agreed that this trial, together with the company's
first late-stage trial, would be adequate to support a New Drug
Application for the drug, Acorda said in a statement.





Read more at Reuters.com Government Filings News